BIO-key International stockholders approved the final outstanding proposal at the company’s 2026 annual meeting, clearing the way for the issuance of shares tied to warrants from an August financing-related transaction. The meeting, first convened in September and adjourned twice, concluded on October 30.
- Stockholders approved the issuance of up to 1,236,668 shares of common stock when warrants issued in BIO-key’s August 10 warrant inducement transaction are exercised.
- The approval was sought to comply with Nasdaq’s rules on issuing shares in certain transactions. It does not itself mean all the shares will be issued; issuance depends on warrant holders exercising their warrants.
- Stockholders had approved the meeting’s first three proposals at the October 2 reconvened session. The October 30 vote addressed the remaining proposal, and no other matters were considered.
The vote authorizes potential additional common shares under the existing warrants. If exercised, those shares would increase the number of BIO-key shares outstanding.